

Transcatheter versus surgical aortic valve replacement in aortic stenosis patients with advanced chronic kidney disease: a systematic review and meta-analysis

Shilin Wei^{1#}, Pengbin Zhang^{1#}, Kerong Zhai¹, Shixiong Wang¹, Weifan Wang¹, Yu Tian¹, Debin Liu¹, Yongnan Li^{1,2}

¹Department of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China; ²Laboratory of Extracorporeal Life Support, Lanzhou University Second Hospital, Lanzhou University, Lanzhou, China

Contributions: (I) Conception and design: S Wei, P Zhang, Y Li, D Liu; (II) Administrative support: None; (III) Provision of study materials or patients: D Liu, Y Li; (IV) Collection and assembly of data: S Wei, P Zhang; (V) Data analysis and interpretation: K Zhai, W Wang, S Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Debin Liu, MD. Department of Cardiac Surgery, Lanzhou University Second Hospital, No. 80, Cuiyingmen, Chengguan District, Lanzhou 730030, China. Email: liudebin01@sina.com; Yongnan Li, PhD. Laboratory of Extracorporeal Life Support, Lanzhou University Second Hospital, No. 80, Cuiyingmen, Chengguan District, Lanzhou 730030, China. Email: lyngyq2006@foxmail.com.

Background: Transcatheter aortic valve replacement (TAVR) has been increasingly used in all levels of risk patients, which is less invasive and has fewer complications. However, the benefits of transcatheter and surgical methods of aortic valve replacement remain controversial for aortic stenosis (AS) patients with advanced chronic kidney disease (stage 3-5).

Methods: We comprehensively searched PubMed, Embase, the Cochrane Library, and the International Clinical Trials Registry Platform (ICTRP) from January 2000 to October 2020 and performed a systematic review to evaluate the two techniques. Two investigators independently conducted the literature searches, study eligibility assessment, and data extraction in duplicate.

Results: Compared to surgical aortic valve replacement (SAVR), TAVR had lower risk of in-hospital mortality [odds ratio (OR): 0.53; 95% confidence interval (CI): 0.36–0.78; P=0.001], lower stroke rate (OR: 0.68; 95% CI: 0.47–0.96; P=0.03), lower risk of acute kidney injury (AKI) (OR: 0.42; 95% CI: 0.34–0.52; P<0.00001) and AKI requiring dialysis (OR: 0.65; 95% CI: 0.58–0.73; P<0.00001), lower rate of bleeding (OR: 0.35; 95% CI: 0.31–0.38; P<0.00001) and blood transfusion (OR: 0.41; 95% CI: 0.32–0.52; P<0.00001), lower infection rate (OR: 0.23; 95% CI: 0.13–0.38; P<0.00001), lower risk of atrial fibrillation (AF) (OR: 0.37; 95% CI: 0.17–0.79; P=0.01) and cardiac tamponade (OR: 0.53; 95% CI: 0.37–0.75; P=0.0003), shorter ICU stay [weighted mean difference (WMD): –2.55; 95% CI: –4.13 to –0.98; P=0.002] and hospital stay (WMD: –7.06; 95% CI: -8.41 to –5.71; P<0.00001).

Discussion: TAVR is a safe, efficient, and feasible technique for AS patients with advanced CKD and probably a better solution for its advantage in reducing in-hospital mortality, postoperative complications, ICU, and hospital stay.

Keywords: Transcatheter aortic valve replacement (TAVR); chronic kidney disease (CKD); aortic stenosis (AS); meta-analysis

Submitted Mar 30, 2021. Accepted for publication May 25, 2021. doi: 10.21037/apm-21-758 View this article at: https://dx.doi.org/10.21037/apm-21-758

Introduction

Aortic stenosis (AS) is one of the most common valvular heart diseases with an estimated prevalence of 12% in patients aged 75 or older and over 25% of them were severe (1). Chronic kidney disease (CKD) is closely related to AS, for patients with CKD lead to calcification of the aortic valve which aggravates AS (2), and low cardiac output caused by AS results in renal dysfunction. Over 19 million patients in the United States are estimated to suffer from CKD or end-stage renal disease (ESRD) (3). Although it is less clear the prevalence of CKD globally, with the rapid increase of hypertension and diabetes, the main causes of CKD (4), the number of CKD patients may be increased as well. And up to 75% of AS patients have some degree of chronic kidney disease before surgery (5). Therefore, AS patients with CKD is becoming a common problem for the cardiologist.

Symptomatic AS carries a grave prognosis without aortic valve replacement (6) and surgical aortic valve replacement (SAVR) used to be the golden standard treatment, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend valve replacement for patients with abnormal aortic valve which reduced systolic opening (7). However, patients with advanced CKD (stage 3-5) are associated with high mortality and complications (8,9) and were regarded as having a higher risk for cardiac surgery than patients without CKD. The first successful transcatheter aortic valve replacement (TAVR) in man has been reported in 2002 (10), and it has been widely used for it is less invasive and has fewer complications. Compared with the medical management of severe AS both SAVR and TAVR improved clinical outcomes by reducing postoperative mortality (11,12). Since patients with advanced CKD were excluded from large randomized controlled trials (RCT) (13-15), it's still less clear whether TAVR is as safe and effective for patients with advanced CKD (stage 3-5).

Since the U.S. Food and Drug Administration has approved TAVR for patients at high surgical risk in 2011, thousands of such devices have been implanted worldwide. The proportion of TAVR has increased significantly, whereas SAVR has decreased. According to the latest study, the volume of TAVR increased by approximately four-fold and SAVR increased by approximately 33% (16). In recent years, many studies compared outcomes between TAVR and SAVR in advanced CKD patients which were neglected and few studies have focused on. So, we performed a systematic review and meta-analysis on pooled data from eligible studies to compare the efficacy and safety between TAVR and SAVR. The study protocol complies with the PRISMA and MOOSE reporting checklists (available at https://dx.doi.org/10.21037/apm-21-758) (17,18).

Methods

Search strategy

We performed a comprehensive online search on PubMed, Embase, the Cochrane Library and the International Clinical Trials Registry Platform (ICTRP) from January 2000 to October 2020 with the following MeSH and EMTREE keywords: transcatheter aortic valve replacement, TAVR, transcatheter aortic valve implantation, surgical aortic valve replacement, SAVR, surgical aortic valve implantation, chronic kidney disease, chronic kidney disease stage 5, renal dysfunction, renal failure, renal insufficiency, end-stage renal disease, and dialysis. No language restrictions were applied.

Study selection

All published studies that included TAVR vs. SAVR in adults with advanced CKD were identified and included. And advanced CKD (stage 3-5) defined as glomerular filtration rate of \leq 59 mL/min/1.73 m² (19). Review articles, animal studies, and non-comparative studies were excluded. When multiple articles for a single study had been published, we used the latest publication to avoid potential overlapping patients in the included studies. Two independent investigators (SL Wei and PB Zhang) conducted the literature searches, study eligibility assessment, and data extraction in duplicate. Discrepancies were resolved by consensus and consultation with experienced reviewers (D Liu and Y Li).

Outcomes

The primary outcomes included in-hospital mortality and postoperative stroke. Secondary clinical outcomes included 1-year mortality, bleeding, blood transfusion, new-onset AF, permanent pacemaker implantation (PPMI) requirement, acute kidney injury (AKI), cardiac tamponade, infection, AKI requiring dialysis, major vascular damage, intensive care unit (ICU) stay and length of stay (LOS). Postoperative stroke was defined as in the hospital or at 30-day follow-up focal deficit regardless of duration time. PPMI requirement was defined as patients with atrioventricular block, bradycardia, sick sinus syndrome or any other situations need PPMI post-procedure. Cardiac tamponade was defined as pericardial effusion discovered by doppler echocardiography post-procedure. AKI was defined as an absolute increase in serum creatinine concentration of $\geq 0.3 \text{ mg/dL}$ ($\geq 26.5 \text{ µmol/L}$) within 48 hours post-procedure or a relative increase of >50% within 7 days from baseline. The definition of AKI requiring dialysis was an AKI necessitating dialysis during the index hospitalization. Major vascular damage was defined as requiring surgical or percutaneous treatment for any access site complication. Bleeding was defined using Valve Academic Research Consortium-2 criteria.

Data abstraction

Data abstraction was carried out by two independent investigators (S Wei and P Zhang) who used a predefined, standardized protocol and data collection tool. Disagreement will be settled through consensus and consultation with experienced reviewers (D Liu and Y Li). We collected basic information of each target study including first author, publication year, study type, sample size, country, study period, outcomes analyzed, type of the population, and proportion of patients. The following baseline characteristics of patients were also gathered, such as: age, gender, hypertension, previous myocardial infarction (MI), heart failure (HF)/New York Heart Association (NYHA) Class, stroke or cerebrovascular disease (CVD), diabetes, coronary artery disease (CAD), peripheral vascular disease (PVD), chronic obstructive pulmonary disease (COPD), AF, and chronic liver disease.

Quality assessment

The Newcastle-Ottawa Quality Assessment Scale (NOS), which consists of 9 questions with 9 possible points for the observational study was used to assess the quality of the included studies, a score ≥ 6 was considered as highquality and a score lower than 6 was defined as poor quality. The details of the assessment process are available in the Table S1. The Jadad Scale which consisted of randomization (0–2 points), blinding (0–2 points) and withdrawals (0–1 point) for assessing the risk of bias was used for randomized studies. Studies scored ≥ 3 points were defined as high quality. Details in Table S2. The quality of all included studies was independently assessed by two investigators (S Wei and P Zhang) and discrepancies were resolved through discussion with experienced reviewers (D Liu and Y Li).

Statistical analysis

Continuous variables were reported as mean (± standard deviation) or median (interquartile range). To convert a median (interquartile range) to a mean (± standard deviation), we used the formulas accepted in the literature (20). Categorical variables were expressed as number and percentage (%). Statistical analysis was performed with RevMan 5.3 software (Cochrane Collaboration, Nordic Cochrane Centre, Copenhagen) to calculate summary effects, which were presented with 95% confidence intervals (CIs). The odds ratio (OR) and mean difference (MD) were separately used as a summary statistic to assess dichotomous data and continuous data. The heterogeneity of the studies was evaluated by the Cochrane χ^2 test (Q) or I², and divided into three groups: as low (25%), moderate (50%), and high heterogeneity (75%). If P value less than 0.1 in the Cochran Q test or I^2 value greater than 50%, a random effects model was utilized otherwise a fixed effects model was applied. P values were two-tailed, and P<0.05 was considered statistically significant.

Results

Eligible studies

The literature search identified 1,264 potentially relevant studies, 664 of these were excluded by reviewing the title and abstract. The remaining 98 studies were excluded after full text evaluation, details in *Figure 1*. After a strict appraisal, 21 studies including 12 propensity score-matched, 8 observational cohort studies, and 1 randomized controlled study were included. Except for 10 studies included in the previous meta-analysis, 2 missed studies and 9 recently published studies were included, 38,989 patients with advanced CKD were incorporated into the data synthesis (16,21-40).

Baseline characteristics of the included studies

Summarized characteristics were displayed in *Table 1*. A total of 38,989 patients from 7 different countries were enrolled (19,678 TAVR *vs.* 19,311 SAVR). There were 12 propensity score-matched studies, 7 retrospective

7160




Figure 1 Flow diagram of the study selection process. ICTRP, the International Clinical Trials Registry Platform; CKD, chronic kidney disease.

observational studies, 1 prospective observational study, and 1 randomized controlled study, and all patients had advanced CKD including CKD stage 3 to 5, end stage renal disease and dialysis. Hypertension (89.8%), CAD (62.7%) and HF (51.8%) were the top three preoperative comorbidities in this population. Preprocedural dialysis patients were included exclusively in 11 studies. Patients in the TAVR group were more likely to be older and to have PVD, CAD, and MI (*Table 2*). Other characteristics were not statistical different between TAVR and SAVR.

Primary outcomes

In-hospital mortality

The in-hospital mortality was reported in 13 studies, and the overall in-hospital mortality was 8.3%. Although we did not find any statistical difference in non-dialysis patients, TAVR was associated with a lower risk of in-hospital mortality compared to SAVR (4.9% vs. 11.7%; OR: 0.53; 95% CI: 0.36–0.78; P=0.001; *Figure 2*). Subgroup analysis also showed that TAVR had a lower risk of in-hospital mortality than SAVR (4.5% vs. 12.7%; OR: 0.49; 95% CI: 0.29–0.84; P=0.01; *Figure 2*).

Stroke

The clinical outcome of stroke was reported in 17 studies, and the overall incidence of stroke was 2.6%. Compared with SAVR, our data indicated that TAVR significantly reduced the risk of stroke (2.1% vs. 3.2%; OR: 0.68; 95% CI: 0.47–0.96; P=0.03; *Figure 3*). In subgroup analysis, dialysis patients had a similar risk of stroke between TAVR and SAVR (*Figure 3*). However, TAVR was associated with a lower risk of stroke compared with SAVR in the non-dialysis group (*Figure 3*).

	Table 1	Baseline	characteristic	cs of the	included	studies
--	---------	----------	----------------	-----------	----------	---------

Study	Nationality	Study type	Population	Study period	TAVR/SAVR, n	Outcomes analyzed	Study quality
Bagur <i>et al.</i>	Canada	Retrospective observational	CKD3-5	2005–2009	119/104	AKI, AKI requiring dialysis	NOS: 6
Rau et al.	Germany	Retrospective observational	Dialysis	2005–2010	15/24	LOS	NOS: 5
Nguyen <i>et al.</i>	United States	Retrospective observational	CKD3-5	2002–2012	162/421	In-hospital mortality, stroke, blood transfusion, AKI, AKI requiring dialysis, LOS, ICU stay, bleeding, AF	NOS: 6
Kobin <i>et al.</i>	United States	Retrospective propensity- matched	Dialysis	2011–2012	194/194	Stroke, LOS	NOS: 8
D'Errigo <i>et al.</i>	Italy	Prospective propensity- matched	CKD3b-5	2010–2012	170/170	Stroke, blood transfusion, AKI, AKI requiring dialysis, ICU stay, cardiac tamponade, major vascular damage, infection	NOS: 7
Alquhtani <i>et al.</i>	United States	Retrospective propensity- matched	Dialysis	2005–2014	197/197	stroke, in-hospital mortality, cardiac tamponade, blood transfusion, LOS, major vascular damage	NOS: 8
Bhise <i>et al.</i>	United States	Retrospective propensity- matched	Dialysis	2012–2013	119/244	In-hospital mortality, blood transfusion, LOS	NOS: 6
Condado <i>et al.</i>	United States	Retrospective observational	ESRD	2007–2015	30/30	stroke, 1-year mortality, PPMI, bleeding major vascular damage, blood transfusion, ICU stay	, NOS: 6
Doshi <i>et al.</i>	United States	Retrospective propensity- matched	CKD4- 5, ESRD excluding dialysis	2012–2014	2,485/2,485	In-hospital mortality, stroke, blood transfusion, AKI, AKI requiring dialysis, LOS, AF, PPMI, cardiac tamponade, major vascular damage, infection	NOS: 8
Kumar e <i>t al.</i>	United States	Retrospective propensity- matched	CKD3-4	2011–2014	1,001/1,001	In-hospital mortality, stroke, blood transfusion, PPMI, major vascular damage, AKI, AKI requiring dialysis	NOS: 8
Shavit <i>et al.</i>	Israel	Prospective observational	CKD3-4	1993–2015	58/111	In-hospital mortality, 1-year mortality, stroke, infection, AKI, LOS	NOS: 6
Alkhalil <i>et al.</i>	United States	Retrospective propensity- matched	Dialysis	2012–2014	175/175	In-hospital mortality, stroke, blood transfusion, LOS, PPMI, infection, bleeding, major vascular damage, cardiac tamponade	NOS: 8
Catalano <i>et al.</i>	United States	Retrospective propensity- matched	ESRD	2008–2017	399/402	In-hospital mortality, 1-year mortality, stroke, infection, AKI, LOS	NOS: 8
Pineda <i>et al.</i>	United States	Randomized controlled trill	CKD3-5 excluding dialysis	NR	244/216	1-year mortality, stroke, bleeding, AKI, major vascular damage, AKI requiring, dialysis, PPMI	Jadad score: 2
Reuillard et al.	France	Retrospective observational	CKD3b-5	2012–2015	73/54	In-hospital mortality, 1-year mortality, blood transfusion, stroke, PPMI, AKI, AKI requiring dialysis, LOS	NOS: 6

Table 1 (continued)

Table 1 (contin	uea)						
Study	Nationality	Study type	Population	Study period	TAVR/SAVR, n	Outcomes analyzed	Study quality
Sanaiha et al.	United States	Retrospective observational	CKD4-5, ESRD	2011–2014	2,323/2,993	In-hospital mortality, stroke, PPMI, LOS	NOS: 7
Ando <i>et al.</i>	United States	Retrospective observational	Dialysis	2013–2017	5,731/6,491	In-hospital mortality, stroke, bleeding, blood transfusion, LOS	NOS: 6
Färber <i>et al.</i>	Germany	Retrospective propensity- matched	Dialysis	2012–2015	661/457	1-year mortality, stroke, blood transfusion, LOS, PPMI, AF, cardiac tamponade, major vascular damage	NOS: 8
Khan <i>et al.</i>	United States	Retrospective propensity- matched	ESRD	2012–2017	1,065/654	In-hospital mortality, stroke, blood transfusion, LOS, PPMI, infections, AF, cardiac tamponade	NOS: 8
Lahoud <i>et al.</i>	England	Retrospective propensity- matched	CKD3-5 excluding dialysis	2007–2017	319/319	In-hospital mortality, stroke, blood transfusion, LOS, bleeding, AKI	NOS: 8

AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disease; NA, not available; LOS, length of stay; AF, atrial fibrillation; PPMI, permanent pacemaker implantation; NOS, New-castle-Ottawa Quality Assessment Scale; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.

Secondary outcomes

1-year mortality

Mentias et al.

United

States

The clinical outcome of 1-year mortality was reported in 6 studies, and the overall 1-year mortality was 28.5%. Our study showed that TAVR could reduce the risk of 1-year mortality (27.7% vs. 29.7%; OR: 0.88; 95% CI: 0.80–0.97; P=0.007; *Figure 4*). There was no statistically significant difference in non-dialysis patients between the 2 groups. But for dialysis patients, TAVR had a lower risk of 1-year mortality than SAVR (28.8% vs. 31.7%; OR: 0.88; 95% CI: 0.80–0.97; P=0.009; *Figure 4*).

Retrospective

propensity-

matched

Dialysis

AKI and AKI requiring dialysis

Ten and eight studies reported the clinical outcome of AKI and AKI requiring dialysis, respectively. The overall incidence of postoperative AKI and AKI requiring dialysis was 32.9% and 14.8%. Pooled analysis showed that SAVR was more likely to have postoperative AKI and AKI requiring dialysis. However, TAVR could not only significantly reduce the incidence of postoperative AKI (40.0% *vs.* 25.3%; OR: 0.42; 95% CI: 0.34–0.52; P<0.00001; *Figure 5A*), but also AKI requiring dialysis (16.7% *vs.* 12.4%; OR: 0.65; 95% CI: 0.58–0.73; P<0.00001; *Figure 5B*).

Bleeding and blood transfusion

2015–2017 4,130/2,565 In-hospital mortality, 1-year mortality,

Six studies reported the incidence of bleeding and 14 studies of the blood transfusion rate. The overall incidence of bleeding and blood transfusion was 16.9% and 30.9%. Pooled data analysis indicated that SAVR significantly increased the risk of bleeding (22.6% vs. 10.4%; OR: 0.35; 95% CI: 0.31–0.38; P<0.00001; *Figure 6A*) and blood transfusion (39.2% vs. 23.0%; OR: 0.41; 95% CI: 0.32–0.52; P<0.00001; *Figure 6B*) compared with TAVR.

stroke, blood transfusion, LOS, PPMI,

AF, major vascular damage, infection

NOS: 7

Infection, major vascular damage, and PPMI requirement

Seven, 9 and 14 studies reported the incidence of infection, major vascular damage, and PPMI requirement, and the overall incidence is 2.8%, 4.3% and 11.3%, respectively. Pooled data analysis indicated that TAVR had lower risk of postoperative infection than SAVR (1.0% vs. 4.9%; OR: 0.23; 95% CI: 0.13–0.38; P<0.00001; *Figure 7A*). However, SAVR significantly decreased the incidence of major vascular damage (5.1% vs. 3.4%; OR: 1.55; 95% CI: 1.08–2.22; P=0.02; *Figure 7B*) and PPMI requirement (15.4% vs. 6.7%; OR: 2.42; 95% CI: 1.82–3.21; P<0.00001; *Figure 7C*).

 Table 1 (continued)

Table 2 Baselin	he Character.	Table 2 Baseline Characteristics of the patients									
Dichotomous	Study (N)	Sample size (N)	Prevalence [N]	Groups % (N)	P value	Continuous	Study (N)	MD 95% CI	Mean	Sample size (N)	P value
Male sex	21	38,989	63.0% [24,550]	TAVR: 61.9 (12,176/19,678); SAVR: 64.1 (12,374/19,311)	0.07						
Diabetes	20	38,626	45.6% [17,623]	TAVR: 48.3 (9,446/19,559); SAVR: 42.9 (8,177/19,067)	0.52						
PVD	19	37,988	29.9% [11,346]	TAVR: 32.9 (6,338/19,240); SAVR: 26.7 (5,008/18,748)	0.0004						
СОРD	18	31,591	29.9% [9,432]	TAVR: 31.0 (4,737/15,259); SAVR: 28.7 (4,695/16,332)	0.17						
Hypertension	17	37,260	89.8% [33,472]	TAVR: 90.2 (17,024/18,876); SAVR: 89.5 (16,448/18,384)	0.56						
CVD	16	26,672	11.4% [3,049]	TAVR: 12.6 (1,598/12,732); SAVR: 10.4 (1,451/13,940)	0.07						
Heart failure	13	36, 190	51.8% [18,760]	TAVR: 57.1 (10,500/18,390); SAVR: 46.4 (8,260/17,800)	0.05						
AF	11	29,255	40.0% [11,716]	TAVR: 40.0 (5,935/14,828); SAVR: 40.1 (5,781/14,427)	0.95						
CAD	10	13,050	62.7% [8,183]	TAVR: 63.6 (4,856/7,632); SAVR: 61.4 (3,327/5,418)	0.03						
W	7	22,096	10.5% [2,312]	TAVR: 13.1 (1,367/10,449); SAVR: 8.1 (945/11,647)	0.01						
Chronic liver disease	7	16,864	6.6% [1,105]	TAVR: 6.9 (623/9,085); SAVR: 6.2 (482/7,779)	0.65						
						Age	18	3.48 (2.24–4.72)	TAVR: 72.6; SAVR: 68.2	TAVR: 16,235; SAVR: 15,073	<0.00001

PVD, peripheral vascular disease; COPD, chronic obstruction pulmonary disease; CVD, stroke or cerebrovascular disease; AF, atrial fibrillation; CAD, coronary artery disease; MI, myocardial

infarction; MD, mean difference; CI, confidence interval; TAVR, transcatheter aortic valve replacement; SAVR, surgical aortic valve replacement.

	TAV	/D	SAV	/D		Odds Ratio		Odds Ratio
Study or Subgroup	Events		Events		Weight	M-H, Random, 95% Cl	Year	
Subgroup analysis				Totui	Weight		reur	
Algahtani2017	101 ulary 12	197 is pat	17	197	6.7%	0.69 [0.32, 1.48]	2017	
Bhise2017	11	119	27	244	6.8%			
Alkhalil2018	14	175	18	175	6.8%			
Sanaiha2019	94	1052	131	1799	8.7%			
Ando2020	266	5731	935	6491	9.0%	0.29 [0.25, 0.33]	2020	-
Khan2020	44	1065	91	654	8.4%			
Mentias2020	124	4130	321	2565	8.9%	0.22 [0.17, 0.27]	2020	
Subtotal (95% CI)		12469		12125	55.3%	0.49 [0.29, 0.84]		
Total events	565		1540					
Heterogeneity: Tau ² =	= 0.47; Ch	$i^2 = 122$	2.14, df =	= 6 (P <	0.00001)	; I ² = 95%		
Test for overall effect	: Z = 2.59	P = 0.	010)					
Subgroup analysis	for non-	dialysi	s patien	ts				
Nguyen2013	12	162	55	461	7.2%	0.59 [0.31, 1.13]	2013	
Doshi2017	154	2485	321	2485	8.9%	0.45 [0.36, 0.54]	2017	
Shavit2018	4	58	14	111	5.0%	0.51 [0.16, 1.64]	2018	
Kumar2018	43	1001	63	1001	8.3%	0.67 [0.45, 0.99]	2018	
Reuillard2019	2	73	3	54	3.0%	0.48 [0.08, 2.97]	2019	· · · · · · · · · · · · · · · · · · ·
Sanaiha2019	93	1271	64	1194	8.5%	1.39 [1.00, 1.94]	2019	
Lahoud2020	2	319	12	319	3.8%		2020	←
Subtotal (95% CI)		5369		5625	44.7%	0.60 [0.36, 0.99]		
Total events	310		532					
Heterogeneity: Tau ² =	= 0.30; Ch	1 ² = 37.	07, df =	6 (P < 0	.00001);	$I^2 = 84\%$		
Test for overall effect	: Z = 2.00	(P = 0.)	05)					
Total (95% CI)		17838		17750	100.0%	0.53 [0.36, 0.78]		•
Total events	875		2072					
Heterogeneity: Tau ² =		$i^2 = 19$		= 13 (P <	0.00001	L): $I^2 = 93\%$		
Test for overall effect						.,		0.1 0.2 0.5 1 2 5 10 Favours TAVR Favours SAVR
Test for subgroup dif				= 1 (P = 0	0.59), I ² =	= 0%		FAVOURS LAVK FAVOURS SAVK
J			,					

Figure 2 Comparison of in-hospital mortality between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).




Figure 3 Compare the risk of stroke between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

А

В




Figure 4 Comparison of 1-year mortality between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

The forest plot for AKI TAVR SAVR Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Year M-H, Random, 95% CI Bagur2010 119 0.29 [0.14, 0.62] 11 27 104 5.9% 2010 Nguyen2013 3 162 26 461 2.8% 0.32 [0.09, 1.06] 2013 D'Errigo2016 49 170 67 170 11.3% 0.62 [0.40, 0.98] 2016 0.49 [0.43, 0.55] Doshi2017 820 2485 1250 2485 21.0% 2017 0.39 [0.32, 0.46] Kumar2018 280 1001 502 1001 19.2% 2018 Shavit2018 58 2.9% 0.61 [0.19, 1.99] 12 2018 4 111 47 399 0.22 [0.15, 0.31] Catalano2019 154 402 13.6% 2019 Pineda2019 23 244 39 216 9.1% 0.47 [0.27, 0.82] 2019 Reuillard2019 20 73 20 54 6.0% 0.64 [0.30, 1.36] 2019 Lahoud2020 18 319 34 319 8.3% 0.50 [0.28, 0.91] 2020 Total (95% CI) 5030 5323 100.0% 0.42 [0.34, 0.52] Total events 1275 2131 Heterogeneity: $Tau^2 = 0.05$; $Chi^2 = 24.87$, df = 9 (P = 0.003); $I^2 = 64\%$ 0.2 0.5 Test for overall effect: Z = 7.89 (P < 0.00001)Favors TAVR Favors SAVR The forest plot for AKI requiring dialysis TAVR SAVR Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl Year M-H, Fixed, 95% CI Bagur2010 119 104 0.27 [0.07, 1.04] 2010 3 9 1.4% Nauven2013 0.44 [0.13, 1.50] 2013 3 162 19 461 1.4% D'Errigo2016 27 170 3.7% 0.51 [0.26, 1.00] 2016 15 170 Doshi2017 499 2485 666 2485 79.2% 0.69 [0.60, 0.78] 2017 ------Kumar2018 35 1001 64 1001 9.2% 0.53 [0.35, 0.81] 2018 Catalano2019 4 399 12 402 1.8% 0.33 [0.11, 1.03] 2019 Pineda2019 15 244 216 2.8% 0.68 [0.34, 1.37] 2019 19




Figure 5 Compare the risk of acute kidney injury (AKI) (A) and AKI requiring dialysis (B) between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

	TAV	'R	SAV	R		Odds Ratio		Odd	s Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fix	ed, 95% CI	
Nguyen2013	2	162	19	461	0.7%	0.29 [0.07, 1.26]	2013		+	
Condado2017	3	30	2	30	0.1%	1.56 [0.24, 10.05]	2017		+	
Alkhalil2018	12	175	15	175	1.0%	0.79 [0.36, 1.73]	2018		+	
Pineda2019	125	244	169	216	6.2%	0.29 [0.19, 0.44]	2019			
Ando2020	544	5731	1514	6491	90.8%	0.34 [0.31, 0.38]	2020			
Lahoud2020	5	319	18	319	1.3%	0.27 [0.10, 0.73]	2020			
Total (95% CI)		6661		7692	100.0%	0.35 [0.31, 0.38]		•		
Total events	691		1737							
Heterogeneity: Chi ²	= 7.61, df	= 5 (P	= 0.18);	$1^2 = 34$	%		Ŀ			1
Test for overall effec	t: Z = 20.1	75 (P <	0.00001)			(0.01 0.1	1 10 Favors SAVR	10
								FAVOIS TAVE	A FAVOIS SAVK	
The forest plot for bl										
	TAV		SAV			Odds Ratio			ls Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I Year	M-H, Rai	ndom, 95% Cl	
Nguyen2013	77	162	336	461	7.6%	0.34 [0.23, 0.49] 2013			
D'Errigo2016	66	170	113	170		0.32 [0.21, 0.50				
D'Errigo2016 Doshi2017	66 949	170 2485	113 1235	170 2485	9.0%	0.32 [0.21, 0.50 0.63 [0.56, 0.70				
	949 86			2485 197	9.0% 7.4%		2017	 	_	
Doshi2017 Alqahtani2017 Bhise2017	949 86 45	2485 197 119	1235 112 113	2485 197 244	9.0% 7.4% 7.0%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10] 2017] 2017] 2017] 2017		_	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017	949 86 45 3	2485 197 119 30	1235 112 113 2	2485 197 244 30	9.0% 7.4% 7.0% 1.5%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05	2017 2017 2017 2017 2017 2017		-	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018	949 86 45 3 62	2485 197 119 30 175	1235 112 113 2 93	2485 197 244 30 175	9.0% 7.4% 7.0% 1.5% 7.2%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74] 2017] 2017] 2017] 2017] 2017] 2018		-	
Doshi 2017 Alqahtani 2017 Bhise 2017 Condado 2017 Alkhali 12018 Kumar 2018	949 86 45 3 62 414	2485 197 119 30 175 1001	1235 112 113 2 93 520	2485 197 244 30 175 1001	9.0% 7.4% 7.0% 1.5% 7.2% 8.7%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78	2017 2017 2017 2017 2017 2017 2018 2018 2018		-	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019	949 86 45 3 62 414 6	2485 197 119 30 175 1001 73	1235 112 113 2 93 520 24	2485 197 244 30 175 1001 54	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30	2017 2017 2017 2017 2017 2017 2018 2018 2018 2018		-	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019 Färber2020	949 86 45 3 62 414 6 593	2485 197 119 30 175 1001 73 661	1235 112 113 2 93 520 24 436	2485 197 244 30 175 1001 54 457	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7% 6.6%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30 0.42 [0.25, 0.70	2017 2017 2017 2017 2017 2018 2018 2018 2018 2019 2020		-	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019 Färber2020 Khan2020	949 86 45 3 62 414 6 593 223	2485 197 119 30 175 1001 73 661 1065	1235 112 113 2 93 520 24 436 262	2485 197 244 30 175 1001 54 457 654	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7% 6.6% 8.6%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30 0.42 [0.25, 0.70 0.40 [0.32, 0.49	2017 2017 2017 2017 2017 2018 2018 2018 2019 2020 2020 2020			
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019 Färber2020 Khan2020 Lahoud2020	949 86 45 3 62 414 6 593 223 53	2485 197 119 30 175 1001 73 661 1065 319	1235 112 113 2 93 520 24 436 262 142	2485 197 244 30 175 1001 54 457 654 319	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7% 6.6% 8.6% 7.6%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30 0.42 [0.25, 0.70 0.40 [0.32, 0.49 0.25 [0.17, 0.36	2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2018 2019 2020 2020 2020 2020			
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019 Färber2020 Khan2020 Lahoud2020 Mentias2020	949 86 45 3 62 414 6 593 223 53 636	2485 197 119 30 175 1001 73 661 1065 319 4130	1235 112 113 2 93 520 24 436 262 142 1103	2485 197 244 30 175 1001 54 457 654 319 2565	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7% 6.6% 8.6% 7.6% 9.0%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30 0.42 [0.25, 0.70 0.40 [0.32, 0.49 0.25 [0.17, 0.36 0.24 [0.22, 0.27	2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2018 2018 2019 2020 2020 2020 2020 2020 2020 2020 2020		- - -	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019 Färber2020 Khan2020 Lahoud2020	949 86 45 3 62 414 6 593 223 53	2485 197 119 30 175 1001 73 661 1065 319	1235 112 113 2 93 520 24 436 262 142	2485 197 244 30 175 1001 54 457 654 319	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7% 6.6% 8.6% 7.6% 9.0%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30 0.42 [0.25, 0.70 0.40 [0.32, 0.49 0.25 [0.17, 0.36	2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2018 2018 2019 2020 2020 2020 2020 2020 2020 2020 2020		- - -	
Doshi2017 Alqahtani2017 Bhise2017 Condado2017 Alkhalil2018 Kumar2018 Reuillard2019 Färber2020 Khan2020 Lahoud2020 Mentias2020	949 86 45 3 62 414 6 593 223 53 636 544	2485 197 119 30 175 1001 73 661 1065 319 4130	1235 112 113 2 93 520 24 436 262 142 1103 1514	2485 197 244 30 175 1001 54 457 654 319 2565 6491	9.0% 7.4% 7.0% 1.5% 7.2% 8.7% 3.7% 6.6% 8.6% 7.6% 9.0%	0.63 [0.56, 0.70 0.59 [0.39, 0.88 0.70 [0.45, 1.10 1.56 [0.24, 10.05 0.48 [0.31, 0.74 0.65 [0.55, 0.78 0.11 [0.04, 0.30 0.42 [0.25, 0.70 0.40 [0.32, 0.49 0.25 [0.17, 0.36 0.24 [0.22, 0.27	2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2017 2018 2019 2020 2020 2020 2020 2020 2020 2020 2020			

Figure 6 Compare the incidence of bleeding (A) and blood transfusion (B) between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

New-onset AF and cardiac tamponade

Five studies reported the incidence of AF and 6 studies the cardiac tamponade. The overall incidence is 25.9% and 1.5% respectively. Pooled analysis showed that TAVR could significantly lower the risk of AF (18.6% vs. 35.2%; OR: 0.37; 95% CI: 0.17-0.79; P=0.01; Figure 8A) and cardiac tamponade (1.1% vs. 2.1%; OR: 0.53; 95% CI: 0.37-0.75; P=0.0003; Figure 8B).

Duration of ICU stay and LOS

Four and 15 studies reported the length of ICU stay and hospital stay. Compared with SAVR, TAVR significantly shortened the time in ICU [weighted mean difference (WMD): -2.55; 95% CI: -4.13 to -0.98; P=0.002; Figure 9A] and hospital (WMD: -7.06; 95% CI: -8.41 to -5.71; P<0.00001; Figure 9B).

Discussion

This meta-analysis incorporated some latest studies which compared the clinical outcomes between TAVR and SAVR in advanced CKD patients. The remarkable findings of this study were even through the patients of TAVR group were older and more likely to have preoperative comorbidities, it reduced the incidence of postoperative in-hospital mortality, stroke and other complications, such as AKI, AKI requiring dialysis, bleeding, blood transfusion, infection, major vascular damage, new-onset AF and cardiac tamponade. Moreover, it shortened the length of ICU stay and hospital stav.

Since the first commercially available transcatheter was implanted (41), TAVR has been widely used for AS patients and randomized clinical trials showed that TAVR to be equal or superior to SAVR in high-risk patients (14,42). However, patients with severe CKD were excluded from these studies, it remains unclear whether TAVR is comparable to SAVR for patients with advanced CKD. In this latest study, the overall in-hospital mortality is much higher with TAVR (3.4% vs. 4.9%) and SAVR (6.5% vs. 11.7%) than the previous study (14). This could be explained by our study focused on severe CKD or dialysis patients, which is associated with a much higher risk of

▲ The forest plot for infection

-									
		TAV		SAV		W-1-1-	Odds Ratio	N	Odds Ratio
	Study or Subgroup					-	M-H, Random, 95% CI		M-H, Random, 95% Cl
	Nguyen2013	3	162	28	461	10.9%	0.29 [0.09, 0.97]		
	D'Errigo2016	10	170	15	170	15.5%	0.65 [0.28, 1.48]		
	Doshi2017	5	2485	55		14.3%	0.09 [0.04, 0.22]		
	Alkhalil2018	1	175	1	175	3.2%	1.00 [0.06, 16.12]		
	Shavit2018	6	58	28	111	13.9%	0.34 [0.13, 0.88]		
	Khan2020		1065	109	654	22.2%	0.21 [0.14, 0.30]		
	Mentias2020	17	4130	90	2565	20.1%	0.11 [0.07, 0.19]	2020	
	Total (95% CI)		8245		6621	100.0%	0.23 [0.13, 0.38]		◆
	Total events	84		326					
	Heterogeneity: Tau ² =				= 6 (P =	0.006); l ²	² = 67%		0.01 0.1 1 10
	Test for overall effect	:: Z = 5.49	9 (P < C	.00001)					Favours TAVR Favours SAVR
	The forest plot for m	najor vas	cular o	damage	•				
		TAV		SAV			Odds Ratio		Odds Ratio
	Study or Subgroup					-	M-H, Random, 95% CI		M-H, Random, 95% Cl
	D'Errigo2016	10	170	0	170	1.5%	22.31 [1.30, 383.82]	2016	
	Doshi2017	109	2485	84	2485	19.4%	1.31 [0.98, 1.75]	2017	
	Alqahtani2017	23	197	22	197	13.3%	1.05 [0.57, 1.96]	2017	
	Condado2017	2	30	1	30	1.9%	2.07 [0.18, 24.15]	2017	
	Alkhalil2018	7	175	11	175	8.4%	0.62 [0.24, 1.64]	2018	
	Kuma = 2019	51	1001	52	1001	17.4%	0.98 [0.66, 1.46]	2018	
	Kumar2018					7 10/	3.72 [1.22, 11.30]	2019	
	Pineda2019	16	244	4	216	7.1%	3.72[1.22, 11.30]		
			244 661	4 9	216 457	7.1%	3.21 [1.54, 6.67]		
	Pineda2019	16 40		9				2020	
	Pineda2019 Färber2020 Mentias2020	16 40	661	9	457 2565	11.5%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67]	2020	
	Pineda2019 Färber2020 Mentias2020 Total (95% CI)	16 40 202	661 4130	9 64	457 2565	11.5% 19.4%	3.21 [1.54, 6.67]	2020	→ ◆
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events	16 40 202 460	661 4130 9093	9 64 247	457 2565 7296	11.5% 19.4% 100.0%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22]	2020	→ →
	Pineda2019 Färber2020 Mentias2020 Total (95% CI)	16 40 202 460 = 0.15; Cł	661 4130 9093 $hi^2 = 2^4$	9 64 247 4.16, df =	457 2565 7296	11.5% 19.4% 100.0%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22]	2020	0.1 0.2 0.5 1 2 5 Favours TAVR Favours SAVR
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect	16 40 202 460 = 0.15; CF :: Z = 2.40	661 4130 9093 $hi^2 = 24$ D (P = 0)	9 64 247 1.16, df = 0.02)	457 2565 7296	11.5% 19.4% 100.0%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22]	2020	0.1 0.2 0.5 1 2 5 Favours TAVR Favours SAVR
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² =	16 40 202 = 0.15; CH :: Z = 2.40 PMI requ	661 4130 9093 hi ² = 24 D (P = 0 uireme	9 64 247 4.16, df = 0.02) ent	457 2565 7296 = 8 (P =	11.5% 19.4% 100.0%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ? = 67%	2020	Favours TAVR Favours SAVR
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect The forest plot for P	16 40 202 = 0.15; Ch :: Z = 2.40 PMI requ	661 4130 9093 $hi^2 = 2^4$ D (P = 0) uireme	9 64 247 4.16, df = 0.02) ent SAN	457 2565 7296 = 8 (P =	11.5% 19.4% 100.0% 0.002); l ²	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio	2020 2020	Favours TAVR Favours SAVR Odds Ratio
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u>	16 40 202 = 0.15; Ch :: Z = 2.40 PMI requ TAV Events	661 4130 9093 $hi^2 = 2^4$ D (P = 0) uireme R Total	9 64 247 4.16, df = 0.02) ent SA Y Events	457 2565 7296 = 8 (P = VR <u>Tota</u>	11.5% 19.4% 100.0% 0.002); I ² I Weight	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI	2020 2020 Year	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015	16 40 202 460 = 0.15; Cf :: Z = 2.40 PMI requ TAV Events 18	$661 \\ 4130 \\ 9093 \\ ni^{2} = 2^{4} \\ 0 (P = 0) \\ uireme \\ 'R \\ Total \\ 194$	9 64 247 4.16, df = 0.02) ent SA <u>Events</u> 15	457 2565 7296 = 8 (P = VR <u>Tota</u> 19 ⁴	11.5% 19.4% 100.0% 0.002); 1 ² <u>I Weight</u> 4 6.4%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio <u>M-H, Random, 95% CI</u> 1.22 [0.60, 2.50]	2020 2020 Year 2015	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016	16 40 202 = 0.15; CH :: Z = 2.40 PMI requ TAV <u>Events</u> 18 29	$661 \\ 4130 \\ 9093 \\ ni2 = 24 \\ 0 (P = 0) \\ uireme \\ r \\ Total \\ 194 \\ 170 \\ $	9 64 247 4.16, df = 0.02) ent SA' <u>Events</u> 15 5	457 2565 7296 = 8 (P = VR <u>Tota</u> 194 170	11.5% 19.4% 100.0% 0.002); 1 ² <u>I Weight</u> 4 6.4% 0 4.7%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ? = 67% Odds Ratio <u>M-H, Random, 95% Cl</u> 1.22 [0.60, 2.50] 6.79 [2.56, 18.00]	2020 2020 Year 2015 2015	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017	16 40 202 460 = 0.15; Cf :: Z = 2.40 PMI requ Events 18 29 26	$661 \\ 4130 \\ 9093 \\ ni2 = 22 \\ 0 (P = 0) \\ uireme \\ R \\ Total \\ 194 \\ 170 \\ 197 $	9 64 247 4.16, df = 0.02) ent SA 4 Events 5 5 11	457 2565 7296 = 8 (P = VR <u>Tota</u> 19 ⁴ 170 197	11.5% 19.4% 100.0% 0.002); I ² 1 Weight 4 6.4% 0 4.7% 7 6.3%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36]	2020 2020 Year 2015 2016 2016	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total (95% Cl) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017	16 40 202 460 = 0.15; Cf :: Z = 2.4(PMI requ TAV Events 18 29 26 6 14	661 4130 9093 hi ² = 2 ⁴ 0 (P = 0 uireme /R Total 194 170 197 119	9 64 247 4.16, df = 0.02) ent SAV Events 5 5 11 25	457 2565 7296 = 8 (P = VR <u>Tota</u> 19 ² 170 197 24 ⁴	11.5% 19.4% 100.0% 0.002); l ² Weight 4 6.4% 0 4.7% 7 6.3%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34]	2020 2020 Year 2015 2016 2017 2017	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017	16 40 202 460 = 0.15; CF :: Z = 2.4(PMI requ TAV Events 18 29 26 14 4	$661 \\ 4130 \\ 9093 \\ mi^2 = 24 \\ 0 (P = 0) \\ uiremee \\ rR \\ Total \\ 194 \\ 197 \\ 197 \\ 197 \\ 197 \\ 30 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ $	9 64 4.16, df = .02) ent SAV Events 15 5 11 25 3	457 2565 7296 = 8 (P = VR <u>Tota</u> 170 197 244 30	11.5% 19.4% 100.0% 0.002); l ² 1 Weight 6.4% 0.4.7% 0.4.7% 6.3% 6.6.% 0.2.4%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67%	2020 2020 Year 2015 2016 2017 2017 2017	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017	16 40 202 460 = 0.15; Cf: :: Z = 2.40 PMI requ TAV Events 29 26 14 4 691	661 4130 9093 hi ² = 24 0 (P = 0 uireme 7 Total 194 197 119 30 2485	9 64 4.16, df = 0.02) ent SAV Events 15 5 11 25 3 3 231	457 2565 7296 = 8 (P = VR <u>Tota</u> 194 197 244 30 2485	11.5% 19.4% 100.0% 0.002); 1 ² 1 Weight 4 6.4% 0 4.7% 7 6.3% 4 6.6% 0 2.4% 5 10.5%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34] 1.38 [0.28, 6.80] 3.76 [3.20, 4.42]	2020 2020 Year 2017 2016 2017 2017 2017 2017	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% Cl) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018	16 40 202 = 0.15; Cf: :: Z = 2.40 PMI requ TAV Events 18 29 26 14 4 691 23	661 4130 9093 hi ² = 2 ⁴ 0 (P = C) uireme R <u>Total</u> 194 170 197 199 300 2485 175	9 64 247 4.16, df = 0.02) ent SA' Events 5 5 11 25 3 231 10	457 2565 7296 = 8 (P = VR <u>Tota</u> 194 170 197 244 300 2485 175	11.5% 19.4% 100.0% 0.002); 1 ² 1 Weight 4 6.4% 0 4.7% 7 6.3% 4 6.6% 0 2.4% 5 0.5%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67% Odds Ratio M-H, Random, 95% Cl 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34] 1.38 [0.28, 6.80] 3.76 [3.20, 4.42] 2.50 [1.15, 5.42]	2020 2020 Year 2015 2015 2017 2017 2017 2017 2017 2017	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total (95% Cl) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018	16 40 202 460 = 0.15; Ch :: Z = 2.4(PMI requ TAV Events 18 29 266 14 4 691 23 88	661 4130 9093 hi ² = 2 ⁴ 0 (P = 0 uireme R Total 194 170 197 119 300 2485 175 1001	9 64 247 4.16, df = .02) ent SA' Events 15 5 11 25 3 231 25 3 231 87	457 2565 7296 = 8 (P = VR Tota 194 170 197 244 30 2485 175 1001	11.5% 19.4% 100.0% 0.002); 1 ² 1 Weight 4 6.4% 5 6.6% 5 10.5% 5 6.0.% 1 9.6%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67%	2020 2020 2020 2015 2015 2016 2017 2017 2017 2017 2018 2018	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019	16 400 202 4600 = 0.15; CH :: Z = 2.40 PMI requ TAV Events 18 29 26 14 4 691 23 88 68	661 4130 9093 hi ² = 24 0 (P = 0 uireme R Total 194 179 197 119 30 2485 175 1001 244	9 64 247 4.16, df = 0.02) ent SA ³ Events 15 5 11 25 3 231 10 87 31	457 2565 7296 = 8 (P = VR <u>Tota</u> 194 197 244 30 2485 1001 216	11.5% 19.4% 100.0% 0.002); 1 ² 100002; 1 ² 10002; 1	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34] 1.38 [0.28, 6.80] 3.76 [3.20, 4.42] 2.50 [1.15, 5.42] 1.01 [0.74, 1.38] 2.31 [1.44, 3.70]	2020 2020 Year 2015 2016 2017 2017 2017 2018 2018 2018 2019	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019	16 40 202 460 = 0.15; Cf :: Z = 2.4(PMI requ TAV Events 18 29 26 14 4 691 23 88 688 682	661 4130 9093 hi ² = 24 D (P = C) uireme R Total 194 179 197 119 30 2485 175 1001 244 73	9 64 247 4.16, df = 0.02) ent SAV Events 15 5 11 25 3 231 10 87 31 1	457 2565 7296 = 8 (P = VR Tota 194 170 197 244 30 2485 175 1001 216 54	11.5% 19.4% 100.0% 0.002); 1 ² 1 Weight Weight 4 6.4% 5 6.4% 5 6.4% 5 6.6% 5 6.0% 5 6.0% 5 8.3%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34] 1.38 [0.28, 6.80] 3.76 [3.20, 4.42] 2.50 [1.15, 5.42] 1.01 [0.74, 1.38] 2.31 [1.44, 3.70] 22.86 [2.97, 175.93]	2020 2020 Year 2015 2016 2016 2017 2017 2017 2017 2017 2018 2018 2018 2019	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total (95% Cl) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019	16 40 202 (10,15; CH (11,12) (661 4130 9093 hi ² = 24 0 (P = C) uireme R Total 194 170 197 199 300 2485 175 1001 2485 175 1001 2432	9 64 247 4.16, df = .02) ent SAV Events 15 5 5 11 25 3 231 10 87 31 10 87 31	457 2565 7296 = 8 (P = VR Tota 194 170 197 244 300 2485 175 1000 2485 175 1000 2495	11.5% 19.4% 100.0% 0.002); 1 ² 1 Weight 4 6.4% 5 6.4% 5 6.0% 5 6.0% 5 9.2,4% 5 6.0% 5 9.6% 5 8.3% 4 1.6%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67%	2020 2020 2020 2020 2017 2015 2016 2017 2017 2017 2017 2018 2019 2019 2019 2019	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% CI
	Pineda2019 Färber2020 Mentias2020 Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019 Färber2020	16 40 202 460 = 0.15; Ch :: Z = 2.4(PMI requ TAV Events 18 29 26 14 4 691 23 88 88 68 22 272 27 120	661 4130 9093 hi ² = 24 0 (P = C) uireme R Total 194 197 119 30 2485 175 1001 244 73 2423 661	9 64 247 4.16, df = 0.02) ent SA'<u>Events</u> 15 5 11 255 3 231 10 87 31 11 4 4 17	457 2565 7296 = 8 (P = VR Tota 194 170 244 30 2485 175 1001 216 54 2993 457	11.5% 19.4% 100.0% 0.002); ² Weight 4 6.6% 0 4.7% 7 6.3% 4 6.6% 0 2.4% 5 10.5% 5 8.3% 4 1.6% 5 10.3% 7 7.9%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34] 1.38 [0.28, 6.80] 3.76 [3.20, 4.42] 2.50 [1.15, 5.42] 1.01 [0.74, 1.38] 2.31 [1.44, 3.70] 22.86 [2.97, 175.93] 2.29 [1.87, 2.80] 5.74 [3.40, 9.69]	2020 2020 2020 2020 2017 2017 2017 2017	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% Cl) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019	16 40 202 (10,15; CH (11,12) (661 4130 9093 hi ² = 24 0 (P = C) uireme R Total 194 170 197 199 300 2485 175 1001 2485 175 1001 2432	9 64 247 4.16, df = 0.02) ent SAX Events 15 5 11 25 3 231 10 87 31 1 1 164 17	457 2565 7296 = 8 (P = VR Tota 194 170 244 30 2485 175 1001 216 54 2993 457	11.5% 19.4% 100.0% 0.002); l ² 1 Weight Weight 4 6.4% 0 4.7% 7 6.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 5 7.7.9% 4 9.2%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] ² = 67% Odds Ratio M-H, Random, 95% CI 1.22 [0.60, 2.50] 6.79 [2.56, 18.00] 2.57 [1.23, 5.36] 1.17 [0.58, 2.34] 1.38 [0.28, 6.80] 3.76 [3.20, 4.42] 2.50 [1.15, 5.42] 1.01 [0.74, 1.38] 2.31 [1.44, 3.70] 22.86 [2.97, 175, 93] 2.29 [1.87, 2.80] 5.74 [3.40, 9.69] 2.06 [1.44, 2.96]	2020 2020 2020 2020 2017 2017 2017 2017	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019 Färber2020 Khan2020 Mentias2020	16 40 202 460 = 0.15; CH :: Z = 2.4(PMI requ TAV Events 18 29 26 14 4 691 23 88 88 68 22 272 120 132 479	661 4130 9093 0 (P = C 0 (P = C 0 (P = C 194 170 197 199 30 2485 175 1001 2445 73 232361 1001 244 430	9 64 247 4.16, df 0.02) ent SA'<u>Events</u> 5 5 11 255 3 231 10 87 31 11 64 47 42 123	457 22565 7296 = 8 (P = VR Tota 194 177 197 244 30 2488 175 2448 175 2448 175 2448 255 54 55 255	11.5% 19.4% 100.0% 0.002); ² Weight 4 6.4% 0 4.7% 6 6.6% 0 2.4% 5 10.5% 5 6.0% 1 0.5% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 9.2% 5 10.3%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] 2 = 67%	2020 2020 2020 2017 2015 2016 2017 2017 2017 2017 2017 2018 2019 2019 2019 2019 2019 2020 2020 2020	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019 Färber2020 Khan2020 Mentias2020	16 40 202 460 = 0.15; Cl :: Z = 2.40 PMI requ TAV Events 18 29 26 14 4 691 23 88 68 82 22 272 120 132 479	661 4130 9093 0 (P = C 0 (P = C 0 (P = C 0 (P = C 194 170 194 170 197 119 30 2485 175 1001 244 73 2323 661 1065	9 64 247 3.16, df 0.02) ent SAV Events 5 11 25 3 231 10 87 31 11 164 17 42 123	457 22565 7296 8 (P = 704 704 194 170 194 2488 2488 107 2095 210 54 54 54 54 55 55 56 54 2565	11.5% 19.4% 100.0% 0.002); l ² 1 Weight Weight 4 6.4% 0 4.7% 7 6.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 4 1.6% 5 8.3% 5 7.7.9% 4 9.2%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] 2 = 67%	2020 2020 2020 2017 2015 2016 2017 2017 2017 2017 2017 2018 2019 2019 2019 2019 2019 2020 2020 2020	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² : Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019 Färber2020 Khan2020 Mentias2020 Total (95% CI) Total events	16 40 202 460 = 0.15; Cl :: Z = 2.4(PMI requ TAV Events 18 29 26 14 4 4 691 23 88 68 22 272 120 132 88 68 22 272 120 138 69 14 4 4 99 26 50 14 14 23 88 88 68 22 272 120 198 1986	661 4130 9093 nl ² = 24 0 (P = C uuiremee R Total 194 170 197 119 300 2485 175 1001 244 733 2323 661 1002 2435 175 1001 244 4130	9 64 247 4.16, df = 0.02) ent SAV Events 15 5 11 15 25 3 231 10 87 31 164 17 42 23 231 10	457 22565 7296 = 8 (P = 194 177 199 194 177 199 244 33 2485 177 1000 210 6 55 2993 455 565 2565	11.5% 19.4% 100.0% 0.002); l ² 1 Weight 4 6.4% 5 6.4% 5 6.4% 6 6.6% 6 6.6% 6 6.6% 6 9.6% 8 10.5% 6 10.5% 6 10.3% 7 .9% 5 100.0%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67%	2020 2020 2020 2017 2015 2016 2017 2017 2017 2017 2017 2018 2019 2019 2019 2019 2019 2020 2020 2020	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl
	Pineda2019 Färber2020 Mentias2020 Total (95% CI) Total events Heterogeneity: Tau ² - Test for overall effect The forest plot for P <u>Study or Subgroup</u> Kobrin2015 D'Errigo2016 Alqahtani2017 Bhise2017 Condado2017 Doshi2017 Alkhalil2018 Kumar2018 Pineda2019 Reuillard2019 Sanaiha2019 Färber2020 Khan2020 Mentias2020	16 40 202 460 = 0.15; CH :: Z = 2.4(FAV Events 18 29 266 14 4 691 23 88 68 22 272 120 132 479 1986 = 0.19; Ch	661 4130 9093 hi ² = 2 ² 0 (P = C 0 (P = C 7 7 104 194 170 197 194 194 170 197 109 2485 75 1001 244 47 2323 661 1065 4130 12667 12867	9 64 247 4.16, df = 0.02) ent SA' Events 15 5 11 25 5 11 25 3 3 231 10 40 87 31 11 42 123 23 164 4 17 765 .04, df =	457 22565 7296 = 8 (P = 194 177 199 194 177 199 244 33 2485 177 1000 210 6 55 2993 455 565 2565	11.5% 19.4% 100.0% 0.002); l ² 1 Weight 4 6.4% 5 6.4% 5 6.4% 6 6.6% 6 6.6% 6 6.6% 6 9.6% 8 10.5% 6 10.5% 6 10.3% 7 .9% 5 100.0%	3.21 [1.54, 6.67] 2.01 [1.51, 2.67] 1.55 [1.08, 2.22] = 67%	2020 2020 2020 2017 2015 2016 2017 2017 2017 2017 2017 2018 2019 2019 2019 2019 2019 2020 2020 2020	Favours TAVR Favours SAVR Odds Ratio M-H, Random, 95% Cl

Figure 7 Comparison of Infection (A) major vascular damage (B) and permanent pacemaker implantation (PPMI) requirement (C) between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

mortality (43). However, TAVR is associated with a much lower in-hospital mortality than SAVR (4.9% vs. 11.7%). The less invasive nature and fewer complications of TAVR might be the main reason. Another explanation could be a higher risk of postoperative AKI in SAVR group. Since Elhmidi *et al.* reported that a higher postoperative AKI rate could increase the in-hospital mortality (44). In subgroup analysis we found TAVR could decrease inhospital mortality in dialysis patients. But such difference disappeared in non-dialysis patients which is consistent with previous studies excluded patients with severe CKD. Our study indicated that SAVR is of significant risk for dialysis patients. Nevertheless, we did not have enough data to do a longer follow-up analysis, although some studies showed that there is no difference in long-term mortality (27,30), we still need more studies to confirm these findings.

The postoperative stroke was closely related to longterm mortality. In this meta-analysis, the risk of stroke was much lower in TAVR group, which is contradicted with the previous study. Possible reasons for this phenomenon could be explained as follows: (I) with the advancement in transcatheter heart valves and the improved operator

Α The forest plot for new-onset atrial fibrillation

	TAV		SAVE			Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Nguyen2013	11	162	141	461	18.1%	0.17 [0.09, 0.31]	2013	
Doshi2017	1039	2485	1250	2485	20.7%	0.71 [0.63, 0.79]	2017	+
Färber2020	181	661	137	457	20.3%	0.88 [0.68, 1.15]	2020	
Khan2020	192	1065	218	654	20.4%	0.44 [0.35, 0.55]	2020	-
Mentias2020	157	4130	587	2565	20.5%	0.13 [0.11, 0.16]	2020	+
Total (95% CI)		8503		6622	100.0%	0.37 [0.17, 0.79]		
Total events	1580		2333					
Heterogeneity: Tau ² = Test for overall effect				= 4 (P	< 0.0000	1); $I^2 = 98\%$		0.05 0.2 1 5 20 Favours TAVR Favours SAVR
		•		/D		Odda Patio		Odde Patio
The forest plot for o	TAV	/R	SAV			Odds Ratio	N	Odds Ratio
The forest plot for a Study or Subgroup	TA\ Events	/R Total	SAV Events	Total	-	M-H, Fixed, 95% Cl		Odds Ratio M-H, Fixed, 95% Cl
The forest plot for a <u>Study or Subgroup</u> D'Errigo2016	TAN Events 9	/R <u>Total</u> 170	SAV Events 5	Total 170	5.3%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62]	2016	
The forest plot for o Study or Subgroup D'Errigo2016 Alqahtani2017	TAV Events 9 1	/R Total 170 197	SAV Events 5 4	Total 170 197	5.3% 4.4%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22]	2016 2017	
The forest plot for or Study or Subgroup D'Errigo2016 Alqahtani2017 Doshi2017	TAN Events 9	/R <u>Total</u> 170 197 2485	SAV Events 5	Total 170 197 2485	5.3% 4.4% 60.8%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72]	2016 2017 2017	
The forest plot for or Study or Subgroup D'Errigo2016 Algahtani2017 Doshi2017 Alkhalil2018	TAX Events 9 1 25 2	/R <u>Total</u> 170 197 2485 175	SAV Events 5 4	Total 170 197 2485 175	5.3% 4.4% 60.8% 5.5%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72] 0.39 [0.08, 2.05]	2016 2017 2017 2018	
The forest plot for o <u>Study or Subgroup</u> D'Errigo2016 Alqahtani2017 Doshi2017 Alkhalil2018 Färber2020	TAV Events 9 1 25 2 3	/R Total 170 197 2485 175 661	SAV Events 5 4 55 5 5 0	Total 170 197 2485 175 457	5.3% 4.4% 60.8% 5.5% 0.7%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72] 0.39 [0.08, 2.05] 4.86 [0.25, 94.38]	2016 2017 2017 2018 2020	
The forest plot for or Study or Subgroup D'Errigo2016 Algahtani2017 Doshi2017 Alkhalil2018	TAX Events 9 1 25 2	/R Total 170 197 2485 175 661	SAV Events 5 4 55 5	Total 170 197 2485 175 457	5.3% 4.4% 60.8% 5.5% 0.7%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72] 0.39 [0.08, 2.05] 4.86 [0.25, 94.38]	2016 2017 2017 2018 2020	
The forest plot for or <u>Study or Subgroup</u> D'Errigo2016 Alqahtani2017 Doshi2017 Alkhalil2018 Färber2020	TAV Events 9 1 25 2 3	/R Total 170 197 2485 175 661	SAV Events 5 4 55 5 5 0	Total 170 197 2485 175 457 654	5.3% 4.4% 60.8% 5.5% 0.7%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72] 0.39 [0.08, 2.05] 4.86 [0.25, 94.38] 0.39 [0.18, 0.84]	2016 2017 2017 2018 2020	
The forest plot for o Study or Subgroup D'Errigo2016 Alqahtani2017 Doshi2017 Alkhalil2018 Färber2020 Khan2020	TAV Events 9 1 25 2 3	/R Total 170 197 2485 175 661 1065 4753	SAV Events 5 4 55 5 5 0	Total 170 197 2485 175 457 654 4138	5.3% 4.4% 60.8% 5.5% 0.7% 23.3%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72] 0.39 [0.08, 2.05] 4.86 [0.25, 94.38] 0.39 [0.18, 0.84]	2016 2017 2017 2018 2020	
The forest plot for or Study or Subgroup D'Errigo2016 Alqahtani2017 Doshi2017 Alkhalil2018 Färber2020 Khan2020 Total (95% CI)	TAX Events 9 1 25 2 3 11	/R Total 170 197 2485 175 661 1065 4753	SAV Events 5 4 55 5 0 17 86	Total 170 197 2485 175 457 654 4138	5.3% 4.4% 60.8% 5.5% 0.7% 23.3% 100.0%	M-H, Fixed, 95% Cl 1.84 [0.61, 5.62] 0.25 [0.03, 2.22] 0.45 [0.28, 0.72] 0.39 [0.08, 2.05] 4.86 [0.25, 94.38] 0.39 [0.18, 0.84]	2016 2017 2017 2018 2020	

Figure 8 Comparison of new-onset atrial fibrillation (A) and cardiac tamponade (B) between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).




Figure 9 Comparison of intensive care unit (ICU) stay (A) and length of stay (LOS) (B) between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

experience, the risk of stroke with TAVR has declined in the general population (45). (II) Our study showed that TAVR had a lower risk of postoperative AF, and it is well known that new-onset AF is associated with a higher risk of stroke (46). In subgroup analysis, pooled analysis found TAVR could lower the risk of stroke in non-dialysis patients, however there was no statistical difference between two groups in dialysis patients. This discrepancy could be

В

explained by those patients on dialysis were associated with platelet dysfunction, hemostatic abnormalities and dialysis patients need frequent anticoagulation therapy during dialysis which result in higher incidences of hemorrhagic stroke than non-dialysis patients (47).

Although both surgical and interventional treatment have a negative impact on renal function, our study demonstrated that the incidence of postoperative AKI and AKI requiring dialysis is much higher in SAVR group, which is consistent with previous studies. There are some possible explains for this phenomenon: (I) bleeding and blood transfusion is more common in SAVR, bleeding could associated hypotension which decreased flow of kidney, and blood transfusion is associated with 3-fold risk of AKI (48); (II) the impact of contrast agent on kidney might be overestimated (49,50); (III) the avoidance of CPB may contribute to lower risk of AKI in TAVR. As far as the author concerned, kidney injury should be minimized during operation since AKI places patients at a 5-fold increased mortality during hospitalization (51). And by minimizing volume of contrast media or reducing the incidence of bleeding and blood transfusion, the risk of postoperative AKI could be decreased further.

Although the risk of PPMI requirement is higher in TAVR group, we found there is a decline in overall PPMI requirement and major vascular damage compared with a previous meta-analysis, this can be explained by advancements in delivery-system, procedural experience, multidisciplinary engagement, and valvular design (52,53). Both bleeding and blood transfusion rate are high which have been reported before (54,55). Since our study focused on severe CKD and dialysis patients, which appears to be associated with platelet dysfunction and hemostatic abnormalities leading to a higher risk for hemorrhagic events (56), and the need for dual antiplatelet therapy after TAVI and SAVR may aggravate the rate of bleeding. The pooled data showed TAVR significantly shortened the stay in ICU and hospital, which is consistent with previous study. TAVR group has fewer complications, which could be the main reason decreased LOS and ICU stay. With the significantly reduce on LOS, it may minimize the potential negative effect on elderly patients. Therefore, TAVR is as safe and efficient as SAVR for patients with advanced CKD.

Limitations

Our meta-analysis has several limitations. First, most of the studies were retrospective observational studies, only one randomized controlled trial included. Although 12 of them did a propensity score-matched manner to get comparable baseline characteristics, eight studies were not matched, potential selection bias could not be ruled out. Moreover, sicker and older patients were more likely to be denied for SAVR, and selection bias may exist at beginning. And there may be a minor overlap in patients included for some studies used the same database. However, excluding these studies would also have excluded patients without any overlap and result in a selection bias. Although we included 21 studies in our meta-analysis, some outcomes scarcely reported may not have enough power to reach a credible conclusion. Second, TAVR is a new technique and with a rapid development, different counties and centers used different delivery-system and different valve design. Moreover, diverse experience for different surgeons is closely related to complications. Therefore, outcomes were inevitably affected by these confounding factors. Third, the specific information on radiation-dose exposure, type of contrast media and volume, valve type, peri and postoperative medication use, severity of stenosis, and concomitant procedures were not available. So, some potential confounders still exist. Forth, there is only one RCT in our meta-analysis, more RCTs will be needed to test the conclusion. And only few studies reported longterm outcomes, we need more evidence in the future to testify long-term efficiency of TAVR for patients with advanced CKD.

Conclusions

Our study demonstrated that TAVR was associated with lower risk of in-hospital and 1-year mortality than SAVR in patients with advanced CKD, especially in dialysis patients. Although TAVR increased the risk of PPMI and major vascular damage, it decreased the risk of stroke, AKI, bleeding, blood transfusion, AKI requiring dialysis, infection, major vascular damage, new-onset AF, cardiac tamponade, ICU stay and LOS. TAVR might be a better selection over SAVR for severe CKD and dialysis patients. More large, prospective, randomized controlled trials are needed to confirm these discoveries.

Acknowledgments

Funding: This work was supported by the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (CY2019-QN01, CY2017-BJ01), and Innovation Fund Project of Colleges and

Wei et al. Transcatheter versus SAVR for CKD patients

Universities in Gansu Province (2020B-028).

Footnote

Reporting Checklist: The authors have completed the PRISMA and MOOSE reporting checklists. Available at https://dx.doi.org/10.21037/apm-21-758

Peer Review File: Available at https://dx.doi.org/10.21037/ apm-21-758

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/apm-21-758). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- 1. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 2013;62:1002-12.
- Rattazzi M, Bertacco E, Del Vecchio A, et al. Aortic valve calcification in chronic kidney disease. Nephrol Dial Transplant 2013;28:2968-76.
- Gupta T, Paul N, Kolte D, et al. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. J Am Heart Assoc 2015;4:e002069.
- Webster AC, Nagler EV, Morton RL, et al. Chronic Kidney Disease. Lancet 2017;389:1238-52.
- Thourani VH, Keeling WB, Sarin EL, et al. Impact of preoperative renal dysfunction on long-term survival for

patients undergoing aortic valve replacement. Ann Thorac Surg 2011;91:1798-806; discussion 806-7.

- Varadarajan P, Kapoor N, Bansal RC, et al. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006;82:2111-5.
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/ AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021;143:e72-e227.
- Edwards FH, Peterson ED, Coombs LP, et al. Prediction of operative mortality after valve replacement surgery. J Am Coll Cardiol 2001;37:885-92.
- Kogan A, Medalion B, Kornowski R, et al. Cardiac surgery in patients on chronic hemodialysis: short and long-term survival. Thorac Cardiovasc Surg 2008;56:123-7.
- Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-8.
- Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
- Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 2002;105:1336-41.
- Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014;63:1972-81.
- Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
- Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016;374:1609-20.
- Ando T, Briasoulis A, Takagi H, et al. Trends of utilization and outcomes after transcatheter and surgical aortic valve replacement on chronic dialysis. J Card Surg 2020;35:3294-301.
- 17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:

7170

explanation and elaboration. BMJ 2009;339:b2700.

- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
- Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
- 20. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
- 21. D'Errigo P, Moretti C, D'Ascenzo F, et al. Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Patients With Chronic Kidney Disease Stages 3b to 5. Ann Thorac Surg 2016;102:540-7.
- 22. Bhise V, Kanade P, Shantha GP, et al. Transcatheter and Surgical Aortic Valve Replacement in Patients With End-Stage Renal Disease. J Am Coll Cardiol 2017;69:1875-6.
- 23. Doshi R, Shah J, Patel V, et al. Transcatheter or surgical aortic valve replacement in patients with advanced kidney disease: A propensity score-matched analysis. Clin Cardiol 2017;40:1156-62.
- Alkhalil A, Golbari S, Song D, et al. In-hospital outcomes of transcatheter versus surgical aortic valve replacement in end stage renal disease. Catheter Cardiovasc Interv 2018;92:757-65.
- 25. Kumar N, Khera R, Garg N, et al. Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Chronic Kidney Disease. Am J Cardiol 2018;121:343-8.
- 26. Shavit L, Silberman S, Tauber R, et al. Outcomes of transcatheter aortic valve implantation compared with surgical aortic valve replacement in geriatric patients with chronic kidney disease Clin Nephrol 2018;90:87-93.
- Pineda AM, Kevin Harrison J, Kleiman NS, et al. Clinical impact of baseline chronic kidney disease in patients undergoing transcatheter or surgical aortic valve replacement. Catheter Cardiovasc Interv 2019;93:740-8.
- Reuillard A, Garrouste C, Pereira B, et al. Evolution of chronic kidney disease after surgical aortic valve replacement or transcatheter aortic valve implantation. Arch Cardiovasc Dis 2019;112:162-70.
- 29. Lahoud R, Butzel DW, Parsee A, et al. Acute Kidney Recovery in Patients Who Underwent Transcatheter

Versus Surgical Aortic Valve Replacement (from the Northern New England Cardiovascular Disease Study Group). Am J Cardiol 2020;125:788-94.

- Mentias A, Desai MY, Saad M, et al. Management of Aortic Stenosis in Patients With End-Stage Renal Disease on Hemodialysis. Circ Cardiovasc Interv 2020;13:e009252.
- 31. Bagur R, Webb JG, Nietlispach F, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. Eur Heart J 2010;31:865-74.
- 32. Nguyen TC, Babaliaros VC, Razavi SA, et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement. J Thorac Cardiovasc Surg 2013;146:1399-406; discussion 13406-7.
- 33. Kobrin DM, McCarthy FH, Herrmann HC, et al. Transcatheter and Surgical Aortic Valve Replacement in Dialysis Patients: A Propensity-Matched Comparison. Ann Thorac Surg 2015;100:1230-6; discussion 6-7.
- 34. Alqahtani F, Aljohani S, Boobes K, et al. Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients on Maintenance Dialysis. Am J Med 2017;130:1464.e1-11.
- 35. Catalano M, Lin D, Cassiere H, et al. Incidence of Acute Kidney Injury in Patients with Chronic Renal Insufficiency: Transcatheter versus Surgical Aortic Valve Replacement. J Interv Cardiol 2019;2019:9780415.
- 36. Sanaiha Y, Mantha A, Ziaeian B, et al. Trends in Readmission and Costs After Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With Renal Dysfunction. Am J Cardiol 2019;123:1481-8.
- 37. Färber G, Bleiziffer S, Doenst T, et al. Transcatheter or surgical aortic valve implantation in chronic dialysis patients: a German Aortic Valve Registry analysis. Clin Res Cardiol 2021;110:357-67.
- Rau S, Wessely M, Lange P, et al. Transcatheter aortic valve implantation in dialysis patients. Nephron Clin Pract 2012;120:c86-90.
- Condado JF, Maini A, Leshnower B, et al. End-stage renal disease and severe aortic stenosis: Does valve replacement improve one-year outcomes? Catheter Cardiovasc Interv 2017;89:1109-15.
- 40. Khan MZ, Khan MU, Kalra A, et al. Transcatheter versus surgical aortic valve replacement in patients with end stage renal disease. Catheter Cardiovasc Interv 2020;96:1102-9.
- Holmes DR, Jr., Nishimura RA, Grover FL, et al. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. J Am Coll Cardiol

Wei et al. Transcatheter versus SAVR for CKD patients

7172

2015;66:2813-23.

- 42. Adams DH, Popma JJ, Reardon MJ. Transcatheter aorticvalve replacement with a self-expanding prosthesis. N Engl J Med 2014;371:967-8.
- 43. Szerlip M, Zajarias A, Vemalapalli S, et al. Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. J Am Coll Cardiol 2019;73:2806-15.
- 44. Elhmidi Y, Bleiziffer S, Deutsch MA, et al. Acute kidney injury after transcatheter aortic valve implantation: incidence, predictors and impact on mortality. Arch Cardiovasc Dis 2014;107:133-9.
- 45. Athappan G, Gajulapalli RD, Sengodan P, et al. Influence of transcatheter aortic valve replacement strategy and valve design on stroke after transcatheter aortic valve replacement: a meta-analysis and systematic review of literature. J Am Coll Cardiol 2014;63:2101-10.
- 46. Lomivorotov VV, Efremov SM, Pokushalov EA, et al. New-Onset Atrial Fibrillation After Cardiac Surgery: Pathophysiology, Prophylaxis, and Treatment. J Cardiothorac Vasc Anesth 2016;30:200-16.
- 47. Wang HH, Hung SY, Sung JM, et al. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis 2014;63:604-11.
- 48. Nuis RJ, Van Mieghem NM, Tzikas A, et al. Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2011;77:881-9.
- 49. Chatani K, Abdel-Wahab M, Wübken-Kleinfeld N, et al. Acute kidney injury after transcatheter aortic valve implantation: Impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term

Cite this article as: Wei S, Zhang P, Zhai K, Wang S, Wang W, Tian Y, Liu D, Li Y. Transcatheter versus surgical aortic valve replacement in aortic stenosis patients with advanced chronic kidney disease: a systematic review and meta-analysis. Ann Palliat Med 2021;10(7):7157-7172. doi: 10.21037/apm-21-758

follow-up. J Cardiol 2015;66:514-9.

- Arrigo M, Maisano F, Haueis S, et al. Transcatheter aorticvalve implantation with one single minimal contrast media injection. Catheter Cardiovasc Interv 2015;85:1248-53.
- 51. Gargiulo G, Sannino A, Capodanno D, et al. Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A metaanalysis of 5,971 patients. Catheter Cardiovasc Interv 2015;86:518-27.
- 52. Vemulapalli S, Carroll JD, Mack MJ, et al. Procedural Volume and Outcomes for Transcatheter Aortic-Valve Replacement. N Engl J Med 2019;380:2541-50.
- 53. Khan SU, Riaz H, Khan MU, et al. Meta-analysis of Temporal and Surgical Risk Dependent Associations With Outcomes After Transcatheter Versus Surgical Aortic Valve Implantation. Am J Cardiol 2019;124:1608-14.
- Winkelmayer WC, Levin R, Avorn J. Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgery. Am J Kidney Dis 2003;41:84-9.
- 55. Dumonteil N, van der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on shortand long-term outcomes after transcatheter aortic valve implantation: a Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. Am Heart J 2013;165:752-60.
- 56. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;156:445-59.

Table S1 Assessment of study quality by NOS

				Qua	ality indica	ators from	NOS			
Study/(Ref. #)		Selection	ı	С	omparabi	ility	Exp	oosure/outco	ome	Score
Bagur et al.	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	6
Rau <i>et al.</i>	Yes	Yes	No	Yes	No	No	Yes	No	Yes	5
Nguyen <i>et al.</i>	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	6
Kobrin <i>et al.</i>	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
D'Errigo <i>et al.</i>	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	7
Alqahtani <i>et al.</i>	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Bhise <i>et al.</i>	Yes	Yes	No	No	Yes	No	Yes	Yes	Yes	6
Condado et al.	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	6
Doshi <i>et al.</i>	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Kumar et al.	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Shavit <i>et al.</i>	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	6
Alkhalil <i>et al.</i>	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Catalano et al.	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Reuillard et al.	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	6
Sanaiha <i>et al.</i>	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	7
Ando <i>et al.</i>	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	6
Färber <i>et al.</i>	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Khan <i>et al.</i>	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Lahoud et al.	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	8
Mentias et al.	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	7

NOS: Newcastle-Ottawa quality assessment Scale. For case-control studies: (1) represents cases with independent validation; (2) cases are consecutive or representative; (3) controls are community; (4) controls have no history of prior cardiac surgery; (5) study controls are comparable for age and sex; (6) study controls for any additional factor(s); (7) cases and controls have the same method of ascertainment; (8) was follow-up long enough for outcomes to occur; and (9) cases and controls have complete follow-up.

Table S2 Quality assessment of RCT with Jadad Score

lite and a		Score Standard		Study
Items	0	1	2	Pineda et al
Randomization	Not randomized or inappropriate method of randomization	The study was described as randomized	The method of randomization was described appropriately	1
Double blinding	No blind or inappropriate method of blinding	The study was described as double blinding	The method of double blinding was described appropriately	0
Withdrawals and dropouts	Not describe the follow-up	A description of withdrawals and dropouts		1
Score summaries				2

The full mark for Jadad Score was 5-point. Scores≥3 was considered with high-quality.